[Special Stock] Samsung Biologics Hits Record High on Surpassing 2 Trillion KRW in H1 Sales

Samsung Biologics hit a 52-week high, driven by strong first-half performance.

As of 9:51 a.m. on the 26th, Samsung Biologics was trading at 915,000 KRW, up 44,000 KRW (5.05%) from the previous close on the KOSPI market. The trading volume was around 130,000 shares, with a trading value of 114.2 billion KRW.

The stock opened at 873,000 KRW and reached an intraday high of 929,000 KRW, setting a new 52-week high. Afterwards, some profit-taking emerged, partially reducing the gains.

On a consolidated basis, Samsung Biologics reported first-half sales of 2.1038 trillion KRW, up 32.56% year-on-year, and operating profit of 655.8 billion KRW, up 47.31%. This is the first time sales have exceeded 2 trillion KRW since the company's founding.

Samsung Biologics stated that the strong performance was due to large-scale orders, increased utilization of Plant 4, and milestone payments received following the approval of biosimilar products by Samsung Bioepis.

This content was produced with the assistance of AI translation services.